Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

TCT 2019 | COMPLETE: Sub-Study to Find Out Complete Optimal Revascularization Timing in STEMI

Courtesy of SBHCI.

The COMPLETE study was carried out to assess the benefit of complete revascularization vs culprit vessel revascularization in the context of ST elevation acute myocardial infarction. This COMPLETE sub-study presented at TCT 2019 scientific sessions simultaneously published in JACC assessed the optimal timing of complete revascularization. The general study had already shown the latter is superior to treating only the culprit vessel. 

Highlights TCT 2019

The sub-study assessed two groups: complete revascularization done during index hospitalization (n=2702) and complete revascularization after discharge (n=1339). Patients in the first group passed through the cath lab again at mean 1 day after infarction and patients in the second group at mean 23 days. 

Outcomes at 3 years for primary end point (composite of death and repeat MI) and secondary end points such as death, MI or ischemia driven revascularization were analyzed in both groups. 

For both the primary and secondary end points, both groups undergoing complete revascularization (during index hospitalization and after discharge) saw a benefit vs. culprit vessel revascularization alone. 

There seems to be no difference between complete revascularization at hospitalization or after discharge and in both arms the major benefit was observed after 45 days of MI. With this data we could speculate that complete revascularization should follow physician criterion on a case by case basis. Given the curves start growing apart more significantly as of day 45, it seems reasonable to do it before this point. 

Courtesy of SBHCI.

Link to the SBHCI publication HERE

Original Title: COMPLETE TIMING SUBSTUDY – A Randomized Trial Of Complete Staged Revascularization Vs. Infarct Artery PCI Alone In Patients With Acute Myocardial Infarction And Multivessel Disease — Importance Of Revascularization Timing.

Author of the Original Article: David A. Wood.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...